BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22118650)

  • 1. [Prevention and treatment of osteoporosis during treatment of non-metastatic prostate cancer].
    Eiken PA; Langdahl BL; Eiken FL; Walter S; Poulsen MH; Abrahamsen B
    Ugeskr Laeger; 2011 Nov; 173(48):3093-6. PubMed ID: 22118650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bone and Men's Health. Hormonal therapy and bone loss in prostate cancer].
    Izumi K; Mizokami A; Namiki M
    Clin Calcium; 2010 Feb; 20(2):175-81. PubMed ID: 20118508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone metastases and bone loss medical treatment in prostate cancer patients.
    Safriadi F
    Acta Med Indones; 2013 Jan; 45(1):76-80. PubMed ID: 23585414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone complications: an increasing risk in patients with prostate cancer.
    J Support Oncol; 2007 Feb; 5(2):88-9. PubMed ID: 17348369
    [No Abstract]   [Full Text] [Related]  

  • 5. [Osteoporosis in castration therapy--a neglected field].
    Bratt O; Akesson K
    Lakartidningen; 2011 Sep 28-Oct 4; 108(39):1902-5. PubMed ID: 22111227
    [No Abstract]   [Full Text] [Related]  

  • 6. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Loss of bone mass in patients with prostate cancer subjected to androgenic deprivation].
    Morote J; Planas J
    Actas Urol Esp; 2011 Apr; 35(4):232-9. PubMed ID: 21419516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis and treatment of osteoporosis in nonmetastatic breast cancer].
    Eiken PA; Hansen M; Kristensen B; Langdahl BL; Abrahamsen B
    Ugeskr Laeger; 2011 Feb; 173(8):577-81. PubMed ID: 21333258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer.
    Wadhwa VK; Weston R; Parr NJ
    BJU Int; 2010 Apr; 105(8):1082-8. PubMed ID: 19912210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Encounter of cancer cells with bone. Cancer treatment-induced bone loss : CTIBL].
    Takahashi S
    Clin Calcium; 2011 Mar; 21(3):447-53. PubMed ID: 21358067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone complications of androgen deprivation therapy: screening, prevention, and treatment.
    Lattouf JB; Saad F
    Curr Opin Urol; 2010 May; 20(3):247-52. PubMed ID: 20224416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer.
    Taxel P; Dowsett R; Richter L; Fall P; Klepinger A; Albertsen P
    BJU Int; 2010 Nov; 106(10):1473-6. PubMed ID: 20456336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
    Kudlacek S; Puntus T
    Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium supplements in patients with prostate cancer.
    Molokwu CN
    BJU Int; 2007 Dec; 100(6):1411. PubMed ID: 17979937
    [No Abstract]   [Full Text] [Related]  

  • 16. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V; Reeves DJ
    J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in bone mineral density in patients with prostate cancer treated with androgen deprivation therapy.
    Bernat MM; Pasini J; Mareković Z
    Coll Antropol; 2005 Dec; 29(2):589-91. PubMed ID: 16417166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
    Smith MR
    Cancer; 2003 Feb; 97(3 Suppl):789-95. PubMed ID: 12548577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer treatment-induced bone loss.
    Adler RA
    Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):442-5. PubMed ID: 17982349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoporosis from androgen deprivation therapy in prostate cancer treatment.
    McLeod N; Huynh CC; Rashid P
    Aust Fam Physician; 2006 Apr; 35(4):243-5. PubMed ID: 16642243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.